Clinical trials: Essential Thrombocythemia (ET), active
Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
The goal of this clinical trial is to learn which of three different doses of Flonoltinib Maleate taken by mouth daily works best to treat adult patients with myelofibrosis in whom the most common approved therapy has failed to…
- Conditions
- Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations
- Trial name
- FM-MF-02 (NCT07750574)
- Testing
- Flonoltinib Maleate orally
- Volunteers
- 105 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Trial name
- NCT07340138
- Testing
- Pelabresib, Ruxolitinib
- Where
- 3 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Polycythemia Vera (PV), Essential Thrombocythemia (ET)
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) comprise a group of clonal hematological malignancies that are characterized by chronic myeloproliferation, splenomegaly, different degrees of bone marrow…
- Trial name
- Ruxo-BEAT (NCT02577926)
- Testing
- Ruxolitinib, BAT
- Where
- 23 sites in Germany
- Volunteers
- 207 people
- Sponsor
- RWTH Aachen University
Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Extended Access of Momelotinib in Adults With Myelofibrosis
The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia…
- Conditions
- Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Trial name
- NCT03441113
- Testing
- MMB
- Where
- 112 sites in United States, Australia and 18 more
- Volunteers
- 237 people
- Sponsor
- GlaxoSmithKline
Essential Thrombocythemia (ET), Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
This study aims to assess the safety and efficacy of orally administered JBI-802 in subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis.
- Conditions
- Essential Thrombocythemia (ET), Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Myeloproliferative Neoplasms (MPN)
- Trial name
- NCT07612280
- Testing
- JBI-802
- Where
- 7 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Jubilant Therapeutics Inc.
Myeloproliferative Neoplasm (MPN), Polycytemia Vera
Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
The goal of this observational study is to learn how the immune system responds to myeloproliferative neoplasms (MPN) in adults with known or suspected MPN.
- Conditions
- Myeloproliferative Neoplasm (MPN), Polycytemia Vera, Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF)
- Trial name
- NCT07590986
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Université Catholique de Louvain
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Study of Canakinumab in Patients With Myelofibrosis
This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF).
- Conditions
- Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis
- Trial name
- NCT05467800
- Testing
- Canakinumab
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- John Mascarenhas
Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF)
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera…
- Conditions
- Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
- Trial name
- NCT05835466
- Testing
- reparixin
- Where
- 9 sites in United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Myelofibrosis, Myelodysplastic Syndrome
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
- Conditions
- Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
- Trial name
- LIMBER (NCT04279847)
- Testing
- INCB057643, Ruxolitinib
- Where
- 48 sites in United States, Canada and 6 more
- Volunteers
- 140 people
- Sponsor
- Incyte Corporation
Multiple Myeloma, Acute Myeloid Leukemia
National Longitudinal Cohort of Hematological Diseases
Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Hemophilia, Hemophilia A
- Trial name
- NICHE (NCT04645199)
- Where
- China
- Volunteers
- 2,300 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Polycythemia Vera, ET (Essential Thrombocythemia)
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood cancers that include polycythemia vera (PV)…
- Conditions
- Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET)
- Trial name
- NCT07362225
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- MPN Research Foundation
Polycythemia Vera (PV), Essential Thrombocythemia (ET)
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
Low-dose MTX is a widely used, inexpensive, and safe therapy used for decades and is well tolerated by patients with rheumatologic diseases. Recently, it was identified as a type 2 JAK inhibitor.
- Conditions
- Polycythemia Vera (PV), Essential Thrombocythemia (ET), Myelofibrosis (MF)
- Trial name
- TREATMORE (NCT06541249)
- Testing
- Methotrexate (MTX)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Essential Thrombocythemia (ET), Myelofibrosis (MF)
Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms
In this study the aim is to investigate the pathogenetic role of extracellular vesicles and senescence in Myeloproliferative Neoplasms.
- Conditions
- Essential Thrombocythemia (ET), Myelofibrosis (MF), Polycythemia Vera (PV)
- Trial name
- NCT06798805
- Where
- 5 sites in Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna